Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sysmex Inostics offers CLIA-certified and CAP-accredited liquid biopsy testing services for oncology applications. Their OncoBEAM™ digital PCR platform and Plasma-SafeSeqS™ NGS panels enable ultra-sensitive detection of low-frequency ctDNA mutations from blood samples. These technologies are used for therapy selection, monitoring response to treatment, minimal residual disease detection in clinical trials and routine care. The company has demonstrated high concordance with tissue-based mutation analysis in real-world studies[3][4][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sysmex Inostics.